Evidence map›Paper›PMID 24958000›Full record

ArticleMetabolites2013

Small Molecule Identification with MOLGEN and Mass Spectrometry.

Markus Meringer, Emma L Schymanski

Abstract read
In one paragraph

Article in Metabolites, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Incorporation ofMolecules (Basel, Switzerland) · 2021
    Article
  6. Article
  7. MetFID: artificial neural network-based compound fingerprint prediction for metabolite annotation.Metabolomics : Official journal of the Metabolomic Society · 2020
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Winners of CASMI2013: Automated Tools and Challenge Data.Mass spectrometry (Tokyo, Japan) · 2014
    Article
  14. Solving CASMI 2013 with MetFrag, MetFusion and MOLGEN-MS/MS.Mass spectrometry (Tokyo, Japan) · 2014
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Markus MeringerDLR: German Aerospace Center, Earth Observation Center (EOC), Münchner Strasse 20, D-82234 Oberpfaffenhofen-Wessling, Germany. markus.meringer@dlr.de.
Emma L SchymanskiEawag: Swiss Federal Institute of Aquatic Science and Technology, Überlandstrasse 133, CH-8600 Dübendorf, Switzerland. emma.schymanski@eawag.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper details the MOLGEN entries for the 2012 CASMI contest for small molecule identification to demonstrate structure elucidation using structure generation approaches. Different MOLGEN programs were used for different categories, including MOLGEN-MS/MS for Category 1, MOLGEN 3.5 and 5.0 for Category 2 and MOLGEN-MS for Categories 3 and 4. A greater focus is given to Categories 1 and 2, as most CASMI participants entered these categories. The settings used and the reasons behind them are described in detail, while various evaluations are used to put these results into perspective. As one author was also an organiser of CASMI, these submissions were not part of the official CASMI competition, but this paper provides an insight into how unknown identification could be performed using structure generation approaches. The approaches are semi-automated (category dependent) and benefit greatly from user experience. Thus, the results presented and discussed here may be better than those an inexperienced user could obtain with MOLGEN programs.

Identifiers

PMID24958000
PMCPMC3901272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.